Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -4K | -2K | -2K | 0 | 0 |
| Operating Income | -4M | -679K | -1M | -2M | -551K |
| EBITDA | -3M | -678K | -1M | -2M | -345K |
| Net Income | -3M | -683K | -1M | -2M | -558K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.67
+0.00% today
1Y Change
+234.00%
Window
Jun 20, 2025 → Jun 11, 2026
Coverage: 251 bars · Jun 20, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Revium Recovery Inc. (RVRC) is a Healthcare stock with a market cap of $100.00M and listed on OTC. The stock last traded around $1.67 and up 234.0% across the available one-year price window (Jun 20, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -145.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -145.9%, free cash flow -92.7% with operating margin 0.0% and ROIC 7.7%. Valuation is more restrained than many high-expectation growth names at P/E 0.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RVRC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVRC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RVRC Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RVRC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$558.0K
+69.0% YoY
Free Cash Flow
-$396.0K
+57.9% YoY
Revenue Growth
+0.0%
EPS Growth
-145.9%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -4K | -2K | -2K | 0 | 0 |
| Operating Income | -4M | -679K | -1M | -2M | -551K |
| EBITDA | -3M | -678K | -1M | -2M | -345K |
| Net Income | -3M | -683K | -1M | -2M | -558K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 530K | 426K | 874K | 1M |
| Total Assets | 19M | 6M | 460K | 1M | 2M |
| Total Liabilities | 360K | 144K | 70K | 64K | 355K |
| Shareholder Equity | 19M | 5M | 390K | 936K | 1M |
| Total Debt | 1K | 1K | 1K | 1K | 163K |
| Net Debt | -3M | -529K | -425K | -873K | -1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
393K
+58.1% YoY
Capital Expenditures
3K
-200.0% YoY
Free Cash Flow
396K
+57.9% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
7.1%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.